Cairo – Mubasher: Renaissance Capital recommended ‘But’ on Cleopatra Hospital stock, setting the target price (TP) at EGP 11.95.
The research firm believes that the company is well positioned to capture the country’s structural top-down growth in an environment of low insurance penetration.
Renaissance expected the company’s earnings before interest, tax, depreciation and amortization (EBITDA) to increase at a 22% compound annual growth rate (CAGR) to 2019.
